Your search for major depressive disorder returned 52 results

AXS-05 consists of dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor.

More than half of individuals with prior COVID-19 illness have met the criteria for symptoms of major depressive disorder.

The goals of this study were to identify functional connectome fingerprints that predict symptom improvement with any treatment and with specific treatment.

The researchers analyzed data from a large randomized noninferiority trial that compared theta-burst stimulation and high-frequency (10 Hz) rTMS delivered to the left dorsolateral prefrontal cortex.

This study addresses the question of whether prescription opioid medications has a potentially causal role in the risk for depression and anxiety disorder.

Investigating whether serial ketamine treatments change functional connectivity between limbic structures and resting-state networks.

Patients received 40 Hz gamma tACS to provide data on the use of varying stimulation periods.

Researchers conducted a study to evaluate the validity of, and satisfaction with, the Cognition KIT DSST mobile app in patients with major depressive disorder.

Researchers conducted an 8-week, open-label, single-arm study and a subsequent 2-stage, sequential, parallel comparison study to assess the use of pimavanserin among patients with Parkinson disease and major depressive disorder.

The influence of gut microbiota extends to the brain via neuroinflammation, resulting in symptoms associated with major depressive disorder.

The Food and Drug Administration (FDA) has granted Fast Track designation to an investigational intranasal formulation of racemic ketamine for the potential treatment of acute suicidal ideation and behavior in patients with major depressive disorder.

Screening recommended for those aged 12 to 18, however there is insufficient evidence to assess for children aged 11 and younger.

Researchers compared how patients experiencing a major depressive episode and control participants perceived contrast patterns.

The percentage of adults with mental health issues increased, as did the percentage reporting that they needed but did not receive help.

Researchers from Dalhousie University in Canada searched publication databases through September of 2020 for articles on ADHD, attention deficit disorder, bipolar disorder, and affective psychosis.

With little being known about the predictors or moderators of dTMS outcome for OCD, this study sought to examine if several theoretically relevant variables may predict and moderate treatment effects including OCD symptom severity, functional impairment, co-occurring depressive symptoms, age, gender, age of OCD onset, and family history of OCD.

While statins have both good and bad outcomes in the realm of neuropsychiatry, researchers looked at the possible associations with statins and suicidality, depression, anxiety, and seizures.

Convergent abnormalities were observed in secondary analyses across portions of the amygdala, hippocampus, subgenual cingulate cortex, and putamen.

Researchers sought to address the possible link between cognitive or mood symptoms and statins.

Transcranial magnetic stimulation (TMS) uses magnetic fields to stimulate nerve cells in the brain.

The drug was found to work quickly in patients with clinical major depression.

Testing for genetic variants may allow clinicians to predict how patients with major depressive disorder metabolize antidepressants.

The FDA has cleared Nexstim’s NBT system for the treatment of major depressive disorder.

HIV-infected adults with major depressive disorder have a 30% increased risk for acute myocardial infarction.

Psilocybin has been shown to have antidepressant properties. With direct comparisons between psilocybin and established treatments for depression lacking, the study researchers looked at psilocybin and escitalopram.

For patients with MDD, the change in scores for depression at six weeks does not differ significantly with psilocybin or psilocybin plus escitalopram.

Researchers performed a double-blind randomized study to investigate the efficacy of tDCS as an augmentation strategy to sertraline in the treatment of vascular depression.

Most older adults with preexisting MDD showed resilience in the first two months of the COVID-19 pandemic, but they express concerns about the future.

The approval was based on the ASPIRE I and II trials that compared the efficacy and safety of esketamine, an N-methyl-D-aspartate receptor antagonist, to placebo in 449 adults with moderate to severe MDD who had active suicidal ideation and intent.

Depression has been linked to elevated markers of inflammation, and aspirin, a nonsteroid, anti-inflammatory medication, can irreversibly inhibit cyclooxygenase-1 and 2.